BRPI0414505A - uso de carboidratos solúveis em água digerìveis e de um ou mais promotores da glutationa, e, composição - Google Patents
uso de carboidratos solúveis em água digerìveis e de um ou mais promotores da glutationa, e, composiçãoInfo
- Publication number
- BRPI0414505A BRPI0414505A BRPI0414505-4A BRPI0414505A BRPI0414505A BR PI0414505 A BRPI0414505 A BR PI0414505A BR PI0414505 A BRPI0414505 A BR PI0414505A BR PI0414505 A BRPI0414505 A BR PI0414505A
- Authority
- BR
- Brazil
- Prior art keywords
- equivalents
- water soluble
- soluble carbohydrates
- promoters
- digestible
- Prior art date
Links
- 150000001720 carbohydrates Chemical class 0.000 title abstract 5
- 235000014633 carbohydrates Nutrition 0.000 title abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title abstract 4
- 108010024636 Glutathione Proteins 0.000 title abstract 2
- 229960003180 glutathione Drugs 0.000 title abstract 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 abstract 2
- 208000031729 Bacteremia Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 abstract 1
- 235000019136 lipoic acid Nutrition 0.000 abstract 1
- 229960002663 thioctic acid Drugs 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
"USO DE CARBOIDRATOS SOLúVEIS EM áGUA DIGERìVEIS E DE UM OU MAIS PROMOTORES DA GLUTATIONA, E, COMPOSIçãO". Um aspecto da presente invenção diz respeito a um método de tratar ou evitar inflamação pulmonar, como uma complicação resultante de trauma físico, bacteremia ou infecção viral, dito método compreendendo administrar entericamente pelo menos um ou mais promotores da glutationa, selecionados de: 0,2-20 g, preferivelmente 0,5-5 g de equivalentes de piruvato; - 0,1 - 5 g, preferivelmente 0,2 - 2 g de equivalentes de oxaloacetato; - 0,01 - 1 g, preferivelmente 0,02 - 0,5 g de equivalentes de ácido lipóico; e pelo menos 20 g de carboidratos solúveis em água digeríveis, na forma de uma composição líquida aquosa, contendo pelo menos 10 g/l de ditos carboidratos solúveis em água digeríveis. Outro aspecto da invenção refere-se a uma composição líquida aquosa, adequada para administração entérica, contendo - 2 a 20 % em peso de carboidratos dissolvidos digeríveis; - dois ou mais promotores da flutationa, selecionados de: 0,5 a 50 g/l de equivalentes de piruvato; 0,05 a 20 g/l de equivalentes de oxaloacetato; 0,05 a 5 g/l de equivalentes da cisteína; e pelo menos 45 % em peso de água.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03077972 | 2003-09-19 | ||
| PCT/NL2004/000649 WO2005027935A1 (en) | 2003-09-19 | 2004-09-20 | Carbohydrate composition and its use for the preparation of a medicament for treating or preventing pulmonary inflammation or acute respiration distress syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414505A true BRPI0414505A (pt) | 2006-11-07 |
Family
ID=34354518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414505-4A BRPI0414505A (pt) | 2003-09-19 | 2004-09-20 | uso de carboidratos solúveis em água digerìveis e de um ou mais promotores da glutationa, e, composição |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070232568A1 (pt) |
| EP (1) | EP1663256A1 (pt) |
| JP (1) | JP2007505898A (pt) |
| CN (1) | CN1882348A (pt) |
| AU (1) | AU2004273758A1 (pt) |
| BR (1) | BRPI0414505A (pt) |
| CA (1) | CA2539364A1 (pt) |
| WO (1) | WO2005027935A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2950254A1 (fr) * | 2009-09-21 | 2011-03-25 | Magnus Kvant | Composition empechant les reactions inflammatoires corporelles |
| CN114425051A (zh) * | 2022-03-07 | 2022-05-03 | 茂名市人民医院 | 硫辛酸在制备治疗脓毒症和/或脓毒性休克的药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69220821T2 (de) * | 1991-02-04 | 1997-11-20 | Nestle Sa | Verfahren zur Sicherstellung eines angemessenen intrazellulären Glutathionspiegels im Gewebe |
| AU701724B2 (en) * | 1994-07-01 | 1999-02-04 | Baxter International Inc. | Biochemically balanced peritoneal dialysis solutions |
| US5821217A (en) * | 1995-10-27 | 1998-10-13 | Beth Israel Deaconess Medical Center, Inc. | Enteral formulation: low in fat and containing protein hydrolysates |
| US5939394A (en) * | 1996-01-18 | 1999-08-17 | Fleming & Company | Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections |
| US5716926A (en) * | 1996-07-26 | 1998-02-10 | Paxton K. Beale | Composition of pyruvate and protein and method for increasing protein concentration in a mammal |
| CN1423528A (zh) * | 2000-04-18 | 2003-06-11 | 雀巢制品公司 | 营养单元 |
| DE10151764A1 (de) * | 2001-10-19 | 2003-05-08 | Basf Ag | Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln |
-
2004
- 2004-09-20 BR BRPI0414505-4A patent/BRPI0414505A/pt not_active IP Right Cessation
- 2004-09-20 WO PCT/NL2004/000649 patent/WO2005027935A1/en not_active Ceased
- 2004-09-20 CA CA002539364A patent/CA2539364A1/en not_active Abandoned
- 2004-09-20 JP JP2006526845A patent/JP2007505898A/ja not_active Withdrawn
- 2004-09-20 AU AU2004273758A patent/AU2004273758A1/en not_active Abandoned
- 2004-09-20 US US10/572,240 patent/US20070232568A1/en not_active Abandoned
- 2004-09-20 EP EP04774952A patent/EP1663256A1/en not_active Withdrawn
- 2004-09-20 CN CNA2004800343400A patent/CN1882348A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005027935A1 (en) | 2005-03-31 |
| AU2004273758A1 (en) | 2005-03-31 |
| JP2007505898A (ja) | 2007-03-15 |
| US20070232568A1 (en) | 2007-10-04 |
| CN1882348A (zh) | 2006-12-20 |
| EP1663256A1 (en) | 2006-06-07 |
| CA2539364A1 (en) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | γ-glutamylcysteine exhibits anti-inflammatory effects by increasing cellular glutathione level | |
| Cai et al. | Inhibition of influenza infection by glutathione | |
| Gasmi et al. | An update on glutathione's biosynthesis, metabolism, functions, and medicinal purposes | |
| Davuluri et al. | Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis | |
| Ren et al. | Dynamic change of hydrogen sulfide during global cerebral ischemia–reperfusion and its effect in rats | |
| Weiss et al. | Aged garlic extract restores nitric oxide bioavailability in cultured human endothelial cells even under conditions of homocysteine elevation | |
| Paul | Cysteine metabolism and hydrogen sulfide signaling in Huntington’s disease | |
| Shi et al. | α-Lipoic acid protects against the cytotoxicity and oxidative stress induced by cadmium in HepG2 cells through regeneration of glutathione by glutathione reductase via Nrf2/ARE signaling pathway | |
| AU5427099A (en) | Use of selenium for treating patients suffering from systemic inflammatory response syndrome (sirs), and composition for implementing said treatment | |
| AR071550A1 (es) | Uso de carbohidratos no digeribles para mejorar la microbiota intestinal | |
| EP2792354A2 (en) | Composition of protectors of acute and chronic hepatic encephalopathy and method for treating acute and chronic hepatic encephalopathy | |
| EP1698624A4 (en) | phenylpropanoic acid derivatives | |
| Zou et al. | Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction | |
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| Bibli et al. | Hydrogen sulfide preserves endothelial nitric oxide synthase function by inhibiting proline-rich kinase 2: implications for cardiomyocyte survival and cardioprotection | |
| AR065640A1 (es) | Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma | |
| BR112015015090A2 (pt) | processos para preservar a função de tecido ou de órgão e para preparar formulação para a mesma e kit respectivo | |
| Owens | Nutritional support to counteract muscle atrophy | |
| Yang et al. | Acute acrylonitrile exposure inhibits endogenous H2S biosynthesis in rat brain and liver: The role of CBS/3-MPST-H2S pathway in its astrocytic toxicity | |
| CA2504872C (en) | Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| Huang et al. | Deoxyshikonin inhibited rotavirus replication by regulating autophagy and oxidative stress through SIRT1/FoxO1/Rab7 axis | |
| BRPI0414505A (pt) | uso de carboidratos solúveis em água digerìveis e de um ou mais promotores da glutationa, e, composição | |
| Bai et al. | Dysregulation of metabolites and high-altitude illnesses development under plateau conditions | |
| Chiol├® ro et al. | Nutritional support during renal replacement therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/715 (2006.01), A23L 33/10 (2016.01), A23L |